Best Case
15%Centralized EVLP recovers a meaningful share of discarded donor lungs while maintaining acceptable graft and survival outcomes.
Forecast dossier
Lung transplantation will scale through centralized organ assessment services
FDA approval of United Therapeutics' LungFX device for centralized ex vivo lung perfusion supports a service model in which donor lungs rejected under standard handling can be shipped to specialized facilities for reassessment before transplant decisions.
Verdict: Centralized lung reassessment is likely to become a larger part of transplant logistics, but it should be adopted with careful outcome tracking because marginal organs carry different risk profiles than standard donor lungs.
Date
Jun 29, 2026
Reliability
76
Harm potential
High
Scenario odds
Baseline
50%Specialized centers expand use gradually, improving access for some patients without transforming national supply immediately.
Adverse Case
25%Costs, logistics, preservation limits, or outcome concerns restrict use to a narrow set of cases.
Wildcard
10%The centralized perfusion network becomes a platform for organ repair, gene editing, or cross-species organ conditioning.
Timeline projections
1-Year
Service preparation
Developments: Lung Bioengineering prepares to add LungFX to centralized EVLP operations.
Risks: Training, logistics, reimbursement, and center adoption may slow rollout.
Outlook: The first year is an operational bridge from approval to service availability.
2-Year
Selective deployment
Developments: More transplant teams use centralized assessment for borderline donor lungs.
Risks: Outcome comparisons may be difficult because recipients and organs differ from standard cases.
Outlook: Clinical confidence builds case by case.
3-Year
Network expansion question
Developments: Demand pressure encourages additional facility capacity or broader geographic routing.
Risks: Transport time and cumulative preservation limits constrain coverage.
Outlook: Logistics becomes as important as device performance.
5-Year
Perfusion-as-a-service
Developments: Centralized organ assessment becomes a recognized transplant service category.
Risks: Payers may resist if incremental transplant costs are high or outcomes are uneven.
Outlook: The model becomes durable if it reduces waitlist deaths at acceptable cost.
10-Year
Organ repair layer
Developments: Perfusion platforms add diagnostics, targeted treatment, and conditioning during assessment.
Risks: More intervention increases regulatory and liability complexity.
Outlook: Assessment evolves toward active organ optimization.
20-Year
Multi-organ logistics platforms
Developments: Centralized preservation and repair networks extend beyond lungs to other transplantable organs.
Risks: Consolidation may create access disparities between connected and disconnected regions.
Outlook: Transplant supply chains become more industrialized.
50-Year
Manufactured and rehabilitated organs
Developments: Perfusion infrastructure supports bioengineered, repaired, or otherwise augmented organs.
Risks: Ethical, cost, and allocation conflicts intensify as supply expands unevenly.
Outlook: The line between organ preservation and organ production blurs.
Planning prompts to verify
- Track 2027 LungFX service rollout locations, participating transplant centers, and case volume.
- Compare LungFX-evaluated transplant outcomes against matched high-risk donor and waitlist alternatives.
- Monitor reimbursement, transport logistics, and preservation-time constraints that determine whether smaller centers can participate.